StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) operating KPIs

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

BeOne Medicines novartis Collaboration Revenue Recognized ($M) ($M)

Form 10-Q / 10-K Collaborative Arrangements Note (XBRL)

QuarterlyAnnual
Latest, Q2 2026
25.3
Period ended Jun 30, 2026
Change on a year earlier
+91.7%
13.2 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNovartis Collaboration Revenue Recognized ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202625.3+91.7%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 202626.1+196.6%Form 10-Q (filed 2026-05-06) ↗
Q4 2025Dec 31, 202521.7+121.4%Form 10-K (filed 2026-02-26) ↗
Q3 2025Sep 30, 202517.3+111.0%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 202513.2+65.0%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20258.80+87.2%Form 10-Q (filed 2026-05-06) ↗
Q4 2024Dec 31, 20249.80+151.3%Form 10-K (filed 2026-02-26) ↗
Q3 2024Sep 30, 20248.20-95.6%Form 10-Q (filed 2025-11-06) ↗
Q2 2024Jun 30, 20248-80.7%Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 20244.70-87.5%Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 20233.90–Form 10-K (filed 2026-02-26) ↗
Q3 2023Sep 30, 2023186–Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 202341.5–Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 202337.5–Form 10-Q (filed 2024-05-08) ↗

Cite this data

StockData. (2026). BeOne Medicines Novartis Collaboration Revenue Recognized ($M) ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/novartis_collab_rev

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.